2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Peter Choyke, MD, FACR, chief of the Molecular Imaging Program, National Cancer Institute, discusses screening in prostate cancer.
Peter Choyke, MD, FACR, chief of the Molecular Imaging Program, National Cancer Institute, discusses screening in prostate cancer.
Conducting random biopsies do not make any sense in a modern world, says Choyke. The best strategy to identify high-grade cancer is MRI, he adds.
In terms of when to operate or radiate, practitioners find that the answer is not perfect—there is a learning curve. A lot of this has to do with good communication between the urologist and radiologist, says Choyke.
Related Content: